IngentaConnect A phase II trial of interleukin-2 in myelodysplastic syndromes

Authors: Nand, Sucha¹; Stock, Wendy²; Stiff, Patrick¹; Sosman, Jeffrey²; Martone, Brenda¹; Radvany, Ruta¹

Source: British Journal of Haematology, Volume 101, Number 1, April 1998 , pp. 205-207(3)

Abstract:

Patients with myelodysplastic syndromes (MDS) show a decrease in the number and function of natural killer (NK) cells, including lymphokine activated killer (LAK) cell activity. Interleukin-2 (IL-2) stimulates the proliferation and activity of these lymphocytes. Anecdotal clinical experience has shown haematological and cytogenetic improvement in myelodysplasia by low-dose IL-2 treatment.

A total of 10 patients with MDS were treated with 1 million units of IL-2 subcutaneously daily for 12 weeks. Even though improvement in CD16⁺/CD56⁺ cell numbers was seen in a majority of the patients, the haematological status and transfusion requirements remained unchanged. There was minimal toxicity from this therapy.

Keywords: myelodysplastic syndromes; interleukin-2; preleukaemia; natural killer cells

Document Type: Research article

DOI: 10.1046/j.1365-2141.1998.00672.x

Affiliations: 1: Section of Hematology/Oncology, Department of Medicine, and Department of Pathology, Loyola University Medical Center, Maywood, Illinois, 2: Section of Hematology/Oncology, Department of Medicine, University of Illinois, Chicago, Illinois, U.S.A.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy